Heparin - Troikaa Pharmaceuticals

Drug Profile

Heparin - Troikaa Pharmaceuticals

Alternative Names: Heparin QPS - Troikaa; Heparin sodium - Troikaa; Heparin sodium topical solution 1000 IU/ml - Triokaa; Phlebotroy QPS

Latest Information Update: 25 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Troikaa Pharmaceuticals
  • Class Anti-infectives; Anti-inflammatories; Antithrombotics; Bronchodilators; Heparins; Mucolytics
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Thrombosis

Most Recent Events

  • 25 Jun 2018 Troikaa Pharmaceuticals plans a phase II/III trial for Phlebitis in India (CTRI/2018/05/013701)
  • 02 May 2017 Troikaa Pharmaceuticals initiates a phase III trial for Thrombosis (Prevention) in India (CTRI2017-03-008263)
  • 30 Mar 2017 Launched for Thrombosis (Prevention) in India prior to March 2017 (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top